Fenbufen

Identification

Name
Fenbufen
Accession Number
DB08981
Type
Small Molecule
Groups
Approved
Description

Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

Structure
Thumb
Synonyms
  • 3-(4-Biphenylylcarbonyl)propionic acid
  • 3-(4-Phenylbenzoyl)propionic acid
  • 4-(4-Biphenylyl)-4-oxobutyric acid
  • 4-Biphenyl-4-yl-4-oxobutanoic acid
  • Fenbufen
  • gamma-oxo(1,1'-Biphenyl)-4-butanoic acid
External IDs
CL 82,204
Categories
UNII
9815R1WR9B
CAS number
36330-85-5
Weight
Average: 254.2806
Monoisotopic: 254.094294314
Chemical Formula
C16H14O3
InChI Key
ZPAKPRAICRBAOD-UHFFFAOYSA-N
InChI
InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
IUPAC Name
4-oxo-4-(4-phenylphenyl)butanoic acid
SMILES
OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fenbufen.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Fenbufen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Fenbufen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Fenbufen is combined with 5-androstenedione.Experimental, Illicit
AbciximabFenbufen may increase the anticoagulant activities of Abciximab.Approved
AcebutololFenbufen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fenbufen.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolFenbufen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fenbufen.Approved, Vet Approved
AclarubicinFenbufen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fenbufen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Aldosterone.Experimental, Investigational
AldoxorubicinFenbufen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid.Approved
AliskirenFenbufen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alminoprofen.Experimental
AlprenololFenbufen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Fenbufen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Amcinonide.Approved
AmikacinFenbufen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideFenbufen may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinFenbufen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodFenbufen may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fenbufen.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Fenbufen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Fenbufen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Fenbufen is combined with Anisodamine.Investigational
AnnamycinFenbufen may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fenbufen.Approved, Investigational
Antithrombin III humanFenbufen may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanFenbufen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Fenbufen is combined with Apocynin.Investigational
ApramycinFenbufen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fenbufen.Approved, Investigational
ArbekacinFenbufen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinFenbufen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanFenbufen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololFenbufen may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Atamestane.Investigational
AtenololFenbufen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fenbufen.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fenbufen.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Fenbufen is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenbufen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Fenbufen.Investigational
BalsalazideFenbufen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminFenbufen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololFenbufen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinFenbufen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Fenbufen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenbufen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fenbufen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Fenbufen is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Fenbufen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Betamethasone.Approved, Vet Approved
BetaxololFenbufen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Fenbufen.Approved, Investigational
BevantololFenbufen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Fenbufen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Fenbufen.Approved, Investigational
BisoprololFenbufen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinFenbufen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololFenbufen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fenbufen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Fenbufen is combined with Bucillamine.Investigational
BucindololFenbufen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Fenbufen is combined with Bufexamac.Approved, Experimental
BufuralolFenbufen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Fenbufen.Approved
BupranololFenbufen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenbufen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fenbufen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Fenbufen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Fenbufen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fenbufen.Approved, Vet Approved, Withdrawn
CarteololFenbufen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolFenbufen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fenbufen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Fenbufen is combined with Celecoxib.Approved, Investigational
CeliprololFenbufen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinFenbufen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fenbufen.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenbufen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fenbufen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fenbufen.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Cilazapril.Approved
CinoxacinFenbufen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidFenbufen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Fenbufen.Vet Approved
CloranololFenbufen may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Fenbufen is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Fenbufen.Experimental
CyclosporineFenbufen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateFenbufen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinFenbufen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidFenbufen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanFenbufen may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinFenbufen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Fenbufen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Fenbufen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Delapril.Experimental
DesirudinFenbufen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Fenbufen.Approved, Investigational
DextranFenbufen may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Fenbufen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Fenbufen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Fenbufen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinFenbufen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Fenbufen is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fenbufen.Approved, Vet Approved
DicoumarolFenbufen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fenbufen.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fenbufen.Approved
DihydrostreptomycinFenbufen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Fenbufen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Fenbufen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Fenbufen.Approved
DoxorubicinFenbufen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneFenbufen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Fenbufen is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Fenbufen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Fenbufen is combined with E-6201.Investigational
Edetic AcidFenbufen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanFenbufen may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Fenbufen is combined with Enalaprilat.Approved
EnoxacinFenbufen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinFenbufen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Fenbufen.Experimental
EpanololFenbufen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Fenbufen is combined with Epirizole.Approved
EpirubicinFenbufen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Fenbufen.Experimental
EplerenoneFenbufen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenbufen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenbufen.Approved
EquileninThe risk or severity of adverse effects can be increased when Fenbufen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Equilin.Approved
EsmololFenbufen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenbufen.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fenbufen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateFenbufen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Fenbufen.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fenbufen.Experimental
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fenbufen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Fenbufen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Feprazone.Experimental
Ferulic acidFenbufen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fenbufen.Approved, Investigational
FleroxacinFenbufen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fenbufen.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fludrocortisone.Approved, Investigational
FluindioneFenbufen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineFenbufen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Fenbufen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fenbufen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Fenbufen.Approved, Nutraceutical, Vet Approved
FondaparinuxFenbufen may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFenbufen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Fenbufen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fosinopril.Approved
FramycetinFenbufen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Fenbufen.Approved, Vet Approved
GabexateFenbufen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinFenbufen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinFenbufen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Fenbufen.Approved, Withdrawn
GemifloxacinFenbufen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinFenbufen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinFenbufen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AFenbufen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Fenbufen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinFenbufen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Fenbufen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Fenbufen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Fenbufen is combined with HE3286.Investigational
HeparinFenbufen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Fenbufen is combined with Higenamine.Investigational
HydralazineFenbufen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenbufen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fenbufen.Approved, Investigational
Hygromycin BFenbufen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fenbufen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fenbufen.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fenbufen.Approved, Investigational
IdarubicinFenbufen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxFenbufen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenbufen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenbufen.Approved
IndenololFenbufen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenbufen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fenbufen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenbufen.Approved, Investigational
IsepamicinFenbufen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fenbufen.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Fenbufen is combined with Istaroxime.Investigational
KanamycinFenbufen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fenbufen.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fenbufen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fenbufen.Approved
LabetalolFenbufen may decrease the antihypertensive activities of Labetalol.Approved
LandiololFenbufen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Fenbufen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Fenbufen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fenbufen.Approved, Investigational
LepirudinFenbufen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanFenbufen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololFenbufen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinFenbufen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Fenbufen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Fenbufen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Fenbufen.Approved
LonazolacThe risk or severity of adverse effects can be increased when Fenbufen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fenbufen.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Fenbufen.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Fenbufen is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fenbufen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Fenbufen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Fenbufen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fenbufen.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fenbufen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Fenbufen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fenbufen.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fenbufen.Approved
MelagatranFenbufen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Fenbufen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fenbufen.Approved, Vet Approved
MepindololFenbufen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineFenbufen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fenbufen.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fenbufen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenbufen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololFenbufen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenbufen.Approved
MetoprololFenbufen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideFenbufen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinFenbufen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fenbufen.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Fenbufen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Fenbufen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Fenbufen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fenbufen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenbufen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Nabumetone.Approved
NadololFenbufen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinFenbufen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatFenbufen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fenbufen.Approved
Nalidixic AcidFenbufen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fenbufen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Fenbufen is combined with NCX 1022.Investigational
NeamineFenbufen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololFenbufen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinFenbufen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinFenbufen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fenbufen.Approved, Investigational
NetilmicinFenbufen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fenbufen.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fenbufen.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Nitroaspirin.Investigational
NorfloxacinFenbufen may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fenbufen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fenbufen.Approved
OlsalazineFenbufen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Fenbufen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Fenbufen is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Orgotein.Vet Approved
OtamixabanFenbufen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fenbufen.Approved
Oxolinic acidFenbufen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololFenbufen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fenbufen.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Fenbufen is combined with Parecoxib.Approved
ParomomycinFenbufen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Parthenolide.Approved, Investigational
PazufloxacinFenbufen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinFenbufen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololFenbufen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateFenbufen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateFenbufen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Perindopril.Approved
PhenindioneFenbufen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonFenbufen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fenbufen.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenbufen.Approved, Investigational
PindololFenbufen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidFenbufen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinFenbufen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Fenbufen.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fenbufen.Approved, Investigational
Piromidic acidFenbufen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenbufen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorFenbufen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinFenbufen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinFenbufen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Fenbufen.Approved
PractololFenbufen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Fenbufen.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Fenbufen can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Fenbufen is combined with Propacetamol.Approved, Investigational
PropranololFenbufen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Fenbufen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Fenbufen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Fenbufen.Vet Approved
Protein CFenbufen may increase the anticoagulant activities of Protein C.Approved
Protein S humanFenbufen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeFenbufen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinFenbufen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fenbufen.Investigational
PuromycinFenbufen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fenbufen.Approved
RamiprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Fenbufen is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fenbufen.Approved, Experimental, Investigational
ReviparinFenbufen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinFenbufen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Risedronate.Approved, Investigational
RivaroxabanFenbufen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Fenbufen is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinFenbufen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinFenbufen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinFenbufen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Fenbufen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fenbufen.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fenbufen.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fenbufen.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenbufen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Fenbufen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Fenbufen.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Fenbufen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fenbufen.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Fenbufen is combined with Serrapeptase.Investigational
SisomicinFenbufen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinFenbufen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Fenbufen.Approved
SotalolFenbufen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CFenbufen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinFenbufen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinFenbufen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Spirapril.Approved
SpironolactoneFenbufen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fenbufen.Investigational
StreptomycinFenbufen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinFenbufen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fenbufen.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fenbufen.Approved, Investigational
SulodexideFenbufen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Fenbufen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fenbufen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Suxibuzone.Experimental
TacrolimusFenbufen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Fenbufen.Approved
TalinololFenbufen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Fenbufen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fenbufen.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fenbufen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Fenbufen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenbufen.Approved, Investigational
TemafloxacinFenbufen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fenbufen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fenbufen.Approved
TertatololFenbufen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fenbufen.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololFenbufen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tixocortol.Approved, Withdrawn
TobramycinFenbufen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenbufen.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Fenbufen.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fenbufen.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenbufen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenbufen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Fenbufen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneFenbufen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenbufen.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Fenbufen is combined with Triptolide.Investigational
TrovafloxacinFenbufen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinFenbufen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Fenbufen.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Fenbufen is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinFenbufen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenbufen.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Fenbufen.Approved
WarfarinFenbufen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranFenbufen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fenbufen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fenbufen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Fenbufen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Fenbufen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fenbufen.Withdrawn
Zoptarelin doxorubicinFenbufen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinFenbufen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,784,701.

General References
Not Available
External Links
KEGG Drug
D01344
PubChem Compound
3335
PubChem Substance
310264942
ChemSpider
3218
BindingDB
50240374
ChEBI
31599
ChEMBL
CHEMBL277522
PharmGKB
PA166049176
Wikipedia
Fenbufen
ATC Codes
M01AE05 — Fenbufen

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)185-187U.S. Patent 3,784,701.
Predicted Properties
PropertyValueSource
Water Solubility0.0121 mg/mLALOGPS
logP3.07ALOGPS
logP3ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)4.22ChemAxon
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity72.49 m3·mol-1ChemAxon
Polarizability27.47 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f89-2900000000-b30afcea40626e90c194

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Biphenyls and derivatives / Butyrophenones / Gamma-keto acids and derivatives / Benzoyl derivatives / Aryl alkyl ketones / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Alkyl-phenylketone / Biphenyl / Butyrophenone / Aryl alkyl ketone / Gamma-keto acid / Benzoyl / Benzenoid / Keto acid / Monocyclic benzene moiety / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
biphenyls, 4-oxo monocarboxylic acid (CHEBI:31599)

Drug created on June 10, 2014 09:46 / Updated on March 02, 2018 03:44